Details

Autor(en) / Beteiligte

• West, Emily
• Zeeb, Marius
• Grube, Christina
• Kuster, Herbert
• Wanner, Katrin
• Scheier, Thomas
• Neumann, Kathrin
• Jörimann, Lisa
• Hampel, Benjamin
• Metzner, Karin J
• Kouyos, Roger D
• Braun, Dominique L
• Günthard, Huldrych F

Titel

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial

Ist Teil von

• Clinical infectious diseases, 2023-10, Vol.77 (7), p.1012-1020

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Starting combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir, reduced immune activation, and less viral diversity compared to starting cART during chronic infection. We report results of a 4-year study designed to determine whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir (DTG) monotherapy. Methods EARLY-SIMPLIFIED is a randomized, open-label, noninferiority trial. People with HIV (PWH) who started cART <180 days after a documented primary HIV-1 infection with suppressed viral load were randomized (2:1) to DTG monotherapy with 50 mg daily or continuation of cART. The primary endpoints were the proportion of PWH with viral failure at 48, 96, 144, and 192 weeks; noninferiority margin was 10%. After 96 weeks, randomization was lifted and patients were permitted to switch treatment groups as desired. Results Of 101 PWH randomized, 68 were assigned to DTG monotherapy and 33 to cART. At week 96 in the per-protocol population, 64/64 (100%) showed virological response in the DTG monotherapy group versus 30/30 (100%) in the cART group (difference, 0.00%; upper bound of 95% confidence interval 6.22%). This demonstrated noninferiority of DTG monotherapy at the prespecified level. At week 192, the study end, no virological failure occurred in either group during 13 308 and 4897 person weeks of follow-up for the DTG monotherapy (n = 80) and cART groups, respectively. Conclusions This trial suggests that early cART initiation during primary HIV infection allows sustained virological suppression after switching to DTG monotherapy. EARLY-SIMPLIFIED is a 4-year open-label trial with randomized and observational phases showing noninferiority of dolutegravir monotherapy versus combination antiretroviral therapy in people with HIV-1 having initiated therapy during primary infection. At 192 weeks, no virological failure occurred in either group. Graphical Abstract Graphical Abstract